After hours: 4:00PM EDT
|Bid||50.35 x 1800|
|Ask||50.36 x 1000|
|Day's Range||50.12 - 50.65|
|52 Week Range||37.47 - 52.19|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.02|
Chairman, President and CEO of Hologic Inc (30-Year Financial, Insider Trades) Stephen P Macmillan (insider trades) sold 194,396 shares of HOLX on 08/05/2019 at an average price of $48.77 a share. Continue reading...
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
In his second "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with Steve MacMillan, president and CEO of Hologic Inc. , the medical equipment maker with shares up 24% for the year. MacMillan explained that Hologic's 3D mammography and cervical products are designed to detect cancers earlier, so patients get better outcomes and the health care system overall saves money. In the daily bar chart of HOLX, below, we can see that prices have moved up so far this year but not without a number of retracements or corrections along the way.
Leo Fasciocco specializes in stocks that have broken out of technical bases; the editor of Ticker Tape Digest reviews two recent buys in the healthcare sector. Both have recently broken out to new all-time highs.
Hologic, Inc. (HOLX), a global leader in women’s health, and SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specialized in ultrasound medical imaging, jointly announce today that Hologic Hub Ltd, a wholly-owned indirect subsidiary of Hologic, Inc., has acquired approximately 46% of SuperSonic Imagine shares, pursuant to a shares sale agreement entered into today. “We are very pleased to take this important step in the process of acquiring SuperSonic Imagine, and are excited to begin integrating the company’s best-in-class ultrasound technology, products and people with Hologic’s broader resources for the benefit of women’s breast health,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. SuperSonic Imagine’s main shareholders, namely Bpifrance, Andera Partners, Auriga Partners, Mérieux Participations and CDC PME Croissance, holding together 10,841,409 shares, representing approximately 46% of the outstanding share capital of SuperSonic Imagine, sold all of their shares to Hologic at a price of €1.50 per share.
Hologic, Inc. announced today that the Company will present at the Canaccord Genuity 39th Annual Growth Conference in New York, NY on Wednesday, August 7 at 10 a.m. Eastern Time.
Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.
Hologic (NASDAQ: HOLX ) unveils its next round of earnings this Wednesday, July 31. Get prepared with Benzinga's ultimate preview for Hologic's Q3 earnings. Earnings and Revenue Analysts expect Hologic ...
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
Hologic’s (Nasdaq: HOLX) Cynosure division announced today the launch of two new products that expand the Company’s growing portfolio of innovative aesthetic treatments — the TempSure® Firm handpiece and a petite mask for SculpSure® submental treatments. SculpSure submental treatments are now cleared by the U.S. Food and Drug Administration (FDA) for patients with a body mass index (BMI) up to 49 — the highest BMI clearance on the market for submental treatments. The TempSure Firm handpiece is the latest addition to the TempSure platform.
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.